Loading…
← CockpitCompetitor Analysis › KIDS OrthoPediatrics Corp.Open in the cockpit ↗

OrthoPediatrics Corp.KIDSCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 98
Mkt cap
$829M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$12.3M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-13.2 pp
WACC 8.9%
Hurdle
n/a
no reverse DCF
Next earnings
124 days
10 Mar 2027
Close · USD$31.76
1D-1.4%
1W+2.9%
1M+46.0%
3M+36.4%
6M+78.3%
YTD+78.8%
1Y+94.0%
ATR %4.8%
Beta0.84
52w lowhigh8.0% off high

What OrthoPediatrics does

Employees: 602

OrthoPediatrics at a glance

Size OrthoPediatrics (KIDS) is a United States Health Care company (Medical Specialties) with a market value of $829M, the 2376th largest of 3,117 United States companies the cockpit tracks. Shares closed at $31.76 on 6 Nov 2026.

Performance Over six months the shares gained 78.3%, against -12.4% for the median peer and -1.1% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 16.1% over the last twelve months (peer median +14.2%); the operating margin is -8.2% (peer median 10.1%).

Valuation It trades at 3.4× enterprise value to sales against a peer median of 2.7× (10th most expensive of 21).

Capital Return on invested capital runs 13.2 points below its cost of capital (8.9% WACC).

Short interest Short interest is 3.7% of the free float (15 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020011 May 202611 Aug 20266 Nov 2026KIDS 185Peer median 88
Six months, rebased to 100: OrthoPediatrics against the median of its 20 peers (local-currency closes).

OrthoPediatrics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$264M$236M$205M$149M$122M
Revenue growth—+15%+38%+22%—
Gross profit$172M$152M$130M$93.9M$77.6M
EBITDA$1.26M-$8.81M-$10.8M-$8.38M-$8.31M
Net income-$33.9M-$39.6M-$37.8M-$21.0M$1.24M
Free cash flow$2.89M-$16.0M-$41.3M-$43.9M-$31.8M
Capital expenditure$11.3M$13.1M$14.9M$19.0M$10.0M
Total debt$106M$117M$84.7M$23.8M$16.7M

Quarterly statements and history in the cockpit →

OrthoPediatrics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%+40%600855688767AMS3004632190688179BBNX77800029501187SETLMCAP304668810836001501VREX301367603367SFLKIDS6-month return →1-month return →
Up and to the right = strong over both horizons. OrthoPediatrics is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%2.5×5×7.5×600855688767AMS3004632190688179BBNX77800029501187SETLMCAP30466881081501VREX301367603367SFLKIDSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OrthoPediatrics is the large dot.

OrthoPediatrics competitors and peer comparison

How OrthoPediatrics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OrthoPediatrics against its 20 peers (data as of 6 Nov 2026)
MeasureKIDSPeer medianRank in peer set
1-month return+46.0%-5.3%highest of 21
6-month return+78.3%-12.4%2nd highest of 21
Distance from 52-week high-8.0%-31.6%3rd highest of 21
Revenue growth (TTM)+16.1%+14.2%10th highest of 21
Operating margin-8.2%10.1%3rd lowest of 21
EV / Sales3.4×2.7×10th most expensive of 21
ROIC minus cost of capital-13.2 pp+1.3 pp3rd lowest of 21
Net debt / EBITDA48.5×-0.2×most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
OrthoPediatrics KIDSUnited States$829M+78%+16%-8%3.4×n/an/a
Beijing Aerospace Changfeng 600855.SSChina$832M-35%-10%-19%5.1×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$824M+5%-4%3%9.7×n/an/a
Advanced Medical Solutions AMS.LUnited Kingdom$824M+14%+6%12%2.9×19.6%+21.4%
Maccura Biotechnology 300463.SZChina$814M-14%-1%-4%2.5×9.2%-10.2%
Zylox-Tonbridge Medical Technology 2190.HKHong Kong$851M-13%+39%25%4.0×5.5%+105.8%
Shanghai Aladdin Biochemical Technology 688179.SSChina$806M-25%+39%26%6.8×21.1%+24.2%
Beta Bionics BBNXUnited States$854M+63%+44%-73%4.9×n/an/a
Menicon 7780.TJapan$854M+12%+5%9%1.4×n/an/a
Allmed Medical Products 002950.SZChina$798M-39%+14%8%1.6×n/an/a
Cofoe Medical Technology 1187.HKHong Kong$798M-27%+40%10%0.9×-8.0%+6.6%
Standard Engineering Technology SETL.NSIndia$796M+164%+26%13%8.9×n/an/a
MedCap MCAP.STSweden$864M+6%+17%15%3.7×2.9%+20.9%
JINS 3046.TJapan$865M-12%+14%10%1.2×-7.2%+11.7%
Sino Medical Sciences Technology 688108.SSChina$868M-35%+22%19%9.1×31.0%+9.9%
Modern Dental 3600.HKHong Kong$871M+19%+12%22%1.7×-7.0%+11.3%
Shanghai INT Medical Instruments 1501.HKHong Kong$784M-25%+35%21%4.1×-2.1%+23.5%
Varex Imaging VREXUnited States$783M-10%+5%8%1.2×n/an/a
BMC Medical 301367.SZChina$780M-13%+37%17%2.0×0.1%+15.6%
Cisen Pharmaceutical 603367.SSChina$890M-15%-6%8%0.8×-12.9%-1.3%
Safilo SFL.MIItaly$890M+24%-4%9%0.8×-0.5%+4.7%

Questions

Which companies are OrthoPediatrics's closest peers?
The cockpit's peer set: Beijing Aerospace Changfeng (600855.SS), Hangzhou Biotest Biotech (688767.SS), Advanced Medical Solutions (AMS.L), Maccura Biotechnology (300463.SZ), Zylox-Tonbridge Medical Technology (2190.HK), Shanghai Aladdin Biochemical Technology (688179.SS), Beta Bionics (BBNX), Menicon (7780.T).
Is OrthoPediatrics expensive compared with its peers?
On ev / sales it trades at 3.4× against a peer median of 2.7×, 10th most expensive of 21 in its peer set.
How has OrthoPediatrics stock performed?
Over six months to 6 Nov 2026 the shares returned +78.3% against -12.4% for the median peer; over one year +94.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.